

Tislelizumab RATIONALE 302

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



Improved QoL



**Serious and disabling adverse effects**



Less serious adverse events observed



**Other adjustments**



Tislelizumab RATIONALE 302

### SCORE

**CURATIVE**




Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: Indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy

Experimental Arm: Tislelizumab

Control Arm: Chemotherapy



